ATH 12.5% 0.5¢ alterity therapeutics limited

prominent ad researcher killed in accident, page-4

  1. 5,882 Posts.
    lightbulb Created with Sketch. 150
    Hi Alois, Merry Christmas
    He was talking about the end of late stage 2-3yr trials which cant be compared with initial evidence from a 12 week trial.
    You may enjoy this link. It looks to me that Mark Smith has been a stand alone effort against the amyloid theory.

    http://blogs.forbes.com/robertlangreth/2010/08/23/renegade-researcher-says-alzheimers-drugs-from-bristol-myers-pfizer-may-be-unsafe-or-ineffective/

    The two comments after the article are interesting.

    He also co wrote the post to the alzforum which concluded with:
    "When seen together with the antioxidant role of A? through copper chelation (Hayashi et al., 2007), the reparative power of the amyloid pathway cannot be questioned "(Rottkamp et al., 2001; Castellani et al., 2009).
    It looks like he was in full agreement with the conclusions from Prana's Cell publication.


 
watchlist Created with Sketch. Add ATH (ASX) to my watchlist
(20min delay)
Last
0.5¢
Change
0.001(12.5%)
Mkt cap ! $23.94M
Open High Low Value Volume
0.4¢ 0.5¢ 0.4¢ $508 124.6K

Buyers (Bids)

No. Vol. Price($)
103 97947018 0.4¢
 

Sellers (Offers)

Price($) Vol. No.
0.5¢ 31179262 15
View Market Depth
Last trade - 11.42am 25/07/2024 (20 minute delay) ?
ATH (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.